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Abstract: Language barrier, race, immigration status, mental health illness, substance abuse and 
socioeconomic status are often not considered when evaluating hepatitis C virus (HCV) sustained 
virological response (SVR) in human immunodeficiency virus (HIV) infection. The influence of 
these factors on HCV work-up, treatment initiation and SVR were assessed in an HIV–HCV co-
infected population and compared to patients with HCV mono-infection. The setting was a publicly 
funded, urban-based, multidisciplinary viral hepatitis clinic. A clinical database was utilized to 
identify HIV and HCV consults between June 2000 and June 2007. Measures of access to HCV 
care (ie, liver biopsy and HCV antiviral initiation) and SVR as a function of the above variables 
were evaluated and compared between patients with HIV–HCV and HCV . HIV–HCV co-infected 
(n = 106) and HCV mono-infected (n = 802) patients were evaluated. HIV–HCV patients were 
more often white (94% versus 84%) and male (87% versus 69%). Bridging fibrosis or cirrhosis 
on biopsy was more frequent in HIV–HCV (37% versus 22%; P = 0.03). HIV infection itself did 
not influence access to biopsy (50% versus 52%) or treatment initiation (39% versus 38%). Race, 
language barrier, immigration status, injection drug history and socioeconomic status did not influ-
ence access to biopsy or treatment. SVR was 54% in HCV and 30% in HIV–HCV (P = 0.003). 
Genotype and HIV were the only evaluated variables to predict SVR. Within the context of a 
socialized, multidisciplinary clinic, HIV–HCV co-infected patients received similar access to HCV 
work-up and care as HCV mono-infected patients. SVR is diminished in HIV–HCV co-infection 
independent of language barrier, race, immigration status, or socioeconomic status.
Keywords: HIV, HCV, sustained virological response, immigrant, language, barrier, race, 
health care access
Introduction
Human immunodeficiency virus (HIV) infection, hepatitis C virus (HCV) genotype, 
HCV RNA level, fibrosis stage and age are well established predictors of sustained 
virological response (SVR) with interferon and ribavirin-based HCV antiviral therapy.1–4 
Language barrier, race, immigration status, mental health illness, history of substance 
abuse, and socioeconomic status are often not considered when evaluating SVR or 
other measures of HCV treatment availability, including access to HCV work-up and 
treatment initiation. This omission may be important, as racial and ethnic disparities 
concerning access to health care are well recognized in many disease states includ-
ing HIV and HCV .5–7 This is relevant given the multilingual and multiracial make-up 
of the HCV-infected population in developed regions of the world,8–10 and the heavy 
burden of mental health illness8,9 and substance abuse10–12 faced by those living with 
HCV . Socioeconomic status is an additional obstacle to health care delivery, even in 
countries with publicly funded health care systems.16–18Therapeutics and Clinical Risk Management 2010:6 208
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The Ottawa Hospital Division of Infectious Disease Viral 
Hepatitis Program provides care for a diverse population of 
HIV–HCV co-infected and HCV mono-infected individuals 
consisting of Canadian-born individuals of multiple races, 
and immigrants from throughout the world. Expertise in viral 
hepatitis, HIV , nursing, and mental health are available as 
part of the basic services offered by the program. Assistance 
with linking to social work and substance abuse programs is 
provided. Services are available in English and French as well 
as in other languages through use of a translator. In this context 
of a publicly funded, diversely populated, urban-located, 
tertiary care hospital-based multidisciplinary viral hepatitis 
program, HCV work-up, treatment initiation and SVR were 
evaluated in a population of HIV–HCV co-infected patients 
and compared to those with HCV mono-infection. Identifying 
and understanding barriers to successful treatment outcomes 
in HIV–HCV co-infection is vital to ensure that optimal care 
is provided to all patients.
Methods
We used a clinical database for this analysis. Patients 
evaluated in clinic from June 2000 to June 2007, 18 years 
of age or older at the time of enrolment, and chronically 
infected with HCV (defined as HCV RNA positive more 
than six months after initial exposure) were included. Patient 
data extracted included HIV status, age, sex, race (White, 
Black, Asian, Aboriginal), primary language, immigration 
status (defined as a foreign-born resident of Canada), 
history of mental health illness, history of injection drug 
use, HBV status, HCV genotype, HCV RNA level, alanine 
aminotransferase (ALT) and aspartate aminotransferase 
(AST) levels. Hepatitis B surface antigen-positive patients 
were excluded from this analysis. If a patient had received 
more than one course of HCV antiviral therapy, only the most 
recent was considered. All formulations of interferon and 
ribavirin HCV antiviral therapy were included. SVR rate was 
defined as HCV RNA negative six months after completion 
of HCV antiviral therapy. A language barrier was defined as 
non-English and non-French speaking.
The 2006 Canadian Census dataset was used to obtain 
information on patient socioeconomic status. Each patient 
was assigned to a census dissemination area using their 
residential postal code. Using this reference point, average 
measures of socioeconomic variables, as represented in the 
census tract denominations, were attributed to each patient. 
The census dissemination-level socioeconomic variables 
included in the analyses were percent of residents with 
post-secondary education, percent of residents who were 
unemployed, percent of residents living below the Canadian 
poverty line, and median before tax neighborhood income.
Outcome measures focused on pre-HCV antiviral therapy 
management, proportion initiating interferon-ribavirin, 
supportive care while on HCV treatment, and SVR. Access to 
pre-HCV-treatment was evaluated by the proportion receiving 
a liver biopsy, because this is considered a standard of care 
procedure for HCV treatment evaluation. This was controlled 
for by genotype in order to account for the potential influence 
of this parameter on biopsy frequency.
Statistical analyses were conducted with SPSS version 
16.0 (SPSS Inc., Chicago, IL). Chi square and t-test analyses 
were used to assess whether a measure of access differed by 
HIV status. Predictors of liver biopsy, treatment initiation 
and SVR were assessed by multivariable logistic regression 
analysis. Genotype, age, fibrosis stage, HCV RNA level, and 
HIV status as well as sex, race, immigration status, language 
category, history of mental health illness and history of 
injection drug use were assessed. We applied a backward 
step regression approach. We considered a P-value of 0.05 
as significant. The Ottawa Hospital Research Ethics Board 
approved this study and patient consent was obtained for 
use of all data.
Results
Between June 2000 and June 2007, 908 patients with 
chronic HCV infection were evaluated, of which 106 
(12%) were HIV–HCV co-infected (Table 1). HIV–HCV 
co-infected patients were more likely to be younger, male, 
Canadian-born, White, and infected with genotypes 1, 2, 
or 3 when compared to HCV mono-infected patients. The 
burden of past injection drug use and mental health illness 
was similar. A language barrier was identified in 4% of HCV 
mono-infected and in none of the HIV–HCV co-infected 
patients. Based on 2006 Canadian Census data, HIV–HCV 
co-infected patient’s financial status was similar to HCV 
mono-infected individuals (Table 1).
Liver biopsy rates were similar between HIV–HCV 
co-infected and HCV mono-infected patients (50% [n = 53] 
versus 52% [n = 415]; P = 0.74). Fewer patients with genotype 
2 or 3 infection underwent liver biopsy compared to other 
genotypes that typically received longer duration therapy 
(96/233 [41%] versus 372/675 [55%]; P  0.001). This was 
true irrespective of HIV positive (11/28 [39%]) or negative 
85/205 [41%]) status (P = 0.83). Despite a younger mean 
age, the proportion of HIV–HCV co-infected patients with 
advanced fibrosis (Stage 3 or 4 by Scherer System) was greater 
than in HCV mono-infection (37% versus 22%; P = 0.03). Therapeutics and Clinical Risk Management 2010:6 209
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Table 1 Baseline patient characteristics
Continuous variables  
mean (standard deviations)
HIV-HCV HCV P value
N (% of Total) 106 (12%) 802 (88%)
Age (years) 42 (7) 45 (10) 0.003
Weight (Kg) 74 (15) 79 (18) 0.03
Mean HCV RNA (IU/mL) 1.33 × 106 (1.41 × 106) 1.72 × 106 (7.00 × 106) 0.59
ALT (IU/L) 78 (53) 82 (69) 0.54
AST (IU/L) 73 (54) 64 (57) 0.16
HIV RNA (copies/mL) 31,001 (78,602) — —
CD4 count (cells/µL) 450 (272) — —
Categorical variables N = 106 N = 802
Male sex 87% 69% 0.001
On HAART at first visit 58% — —
HIV RNA below lower limit of detection 49% — —
Immigrant 9% 22% 0.003
History of mental health illness 47% 49% 0.72
History of injection drug use 58% 57% 0.46
Bridging fibrosis or cirrhosis on biopsy 37% 22% 0.03
HCV RNA  600,000 copies/mL 67% 55% 0.03
Genotype
1 70% 68% 0.64
2 4% 8% 0.07
3 22% 17% 0.13
4 4% 5% 0.55
5 0 1% —
6 0 1% —
Self-reported race 0.03 (overall)
White 94% 84% 0.02
Black 6% 8% 0.68
Asian 0 5% —
Aboriginal 0 3% —
Spoken language 0.20 (overall)
English 74% 78% 0.27
French 26% 18% 0.03
Chinese/Vietnamese 0 2% —
Arabic 0 1% —
Other 0 1% —
Socioeconomic
Yearly median neighborhood income (Canadian dollars) $26,157 $27,937 0.11
Low income strata1 20% 19% 0.52
Urban setting 83% 86% 0.52
High school education 77% 78% 0.29
Bachelors degree or Higher 22% 25% 0.16
Unemployment 7.5% 7.6% 0.88
Notes: 1Defined as bottom quintile.Therapeutics and Clinical Risk Management 2010:6 210
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By univariate logistic regression, individuals with genotype 
1 (odds ratio [OR] 1.79 [1.35, 2.37]; P  0.001), mental 
health illness (OR 1.34 [1.03, 1.74]; P = 0.03), and history 
of injection drug use (OR 1.33 [1.03, 1.74]; P = 0.03] were 
more likely to undergo liver biopsy. Only genotype remained 
significant by multivariate analysis (OR 1.73 [1.31, 2.31]; 
P  0.001].
The proportion of HIV–HCV co-infected patients 
initiating treatment (39% [n = 41]) was similar to HCV 
mono-infected patients (38% [n = 304]) (P = 0.88). 
Genotype 2 and 3 infected patients were not more likely to 
initiate therapy than those with genotype 1, 4, 5 or 6 infec-
tion if HIV seropositive (11/28 [39%] versus 30/78 [38%]; 
P = 0.94]. This was in contrast to HIV seronegative patients 
(94/205 [46%] versus 210/596 [35%]; P = 0.07)]. HCV 
mono-infected females were less likely to initiate therapy than 
males (79/246 [32%] versus 225/556 [40%]; P = 0.03) but 
not when HIV–HCV co-infected (6/14 [43%] versus 35/92 
[38%]; P = 0.73). Advanced fibrosis (OR 2.35 [1.48, 3.73]; 
P  0.001), male sex (OR 1.38 [1.02, 1.87]; P = 0.04) and 
older age (OR 1.02 [1.00, 1.03]; P = 0.02) predicted treatment 
initiation (univariate regression analysis). Advanced fibrosis 
remained significant (OR 2.50 [1.56, 4.03]; P  0.001) as a 
predictor of treatment initiation when these variables were 
controlled for. Socioeconomic factors did not influence the 
likelihood of treatment initiation (data not shown).
Overall, SVR was achieved in 51% of patients (162/316) 
initiating HCV therapy with available final treatment outcome 
data. SVR rates differed by HIV status (12/40 [30%] versus 
150/275 [55%]; P = 0.004) (Figure 1). This was consistent for 
specific genotypes. Genotype 1 status (OR 2.73 [1.60, 4.63]; 
P  0.001) and HIV infection (OR 2.70 [1.26, 5.81]; P = 0.01) 
were key predictors of reduced SVR. Immigration status, 
language category, mental health illness, history of substance 
use and socioeconomic status did not influence SVR in this 
cohort of treatment recipients (data not shown).
Although limited by sample size, the influence of 
combination antiretroviral therapy (cART) on outcome 
measures was evaluated in HIV–HCV co-infected patients. 
Thirty-four of 41 (83%) HIV seropositive patients were on 
cART at the time that HCV antiviral treatment was initiated. 
The mean CD4 count was 549 (274) cells/µL in those 
on therapy and 524 (161) cells/µL in those not receiving 
antiretroviral therapy (P = 0.81). Liver biopsy rates were 
similar between those receiving cART (22 of 34 [65%]) and 
those not (4 of 7 [57%]) (P = 0.71). Erythropoietin use was 
required in 10 of 34 (29%) cART recipients and 0 of 7 (0%) 
patients receiving no HIV treatment (P = 0.11). Erythropoietin 
use was greater in zidovudine recipients: 4 of 7 (57%) versus 6 
of 27 (22%) (P = 0.07). SVR was achieved in 10 of 33 (30%) 
and 2 of 7 (29%) individuals, respectively (P = 0.93). Abacavir 
was used in 2 of 10 (20%) cART-treated patients achieving 
a SVR and 8 of 23 (35%) who did not (P = 0.40).
Discussion
HIV and HCV frequently co-exist. As a consequence, liver 
disease is a primary cause of morbidity and mortality in 
HIV .13 HIV co-infection accelerates progression to cirrhosis, 
liver failure and liver-specific death.14,15 Although sustained 
virological response (SVR) is diminished in HIV–HCV 
co-infection,1,4 successful clearance of chronic HCV infection 
with antiviral therapy reduces liver fibrosis and inflammation 
which presumably prevents cirrhosis, liver failure and 
liver-specific death. The risk of antiretroviral-related 
hepatotoxicity may also be reduced.
In spite of these potential benefits the majority of 
HIV–HCV co-infected patients do not initiate HCV antiviral 
therapy as a consequence of multiple concurrent barriers to 
care.16–18 HIV infection itself has been identified as a potential 
barrier to the provision of health care.19 Even if not overt, 
unrecognized biases may influence access to work-up and 
care in this population. Our analysis suggests that within a 
specialized and multidisciplinary publicly-funded clinic there 
are well-recognized barriers to HCV work-up and treatment 
initiation that can be overcome to maximize the level of care 
provided to those living with HCV . In our evaluation, this 
was true irrespective of HIV status. Multidisciplinary models 
for the treatment of HIV have been proven to be effective.20 
A publicly funded, multidisciplinary clinical care model for 
HIV–HCV co-infected patients including integrated support 
from addiction medicine, mental health, and social work may 
also provide positive outcomes. 
Our analysis suggests that patients with a history of mental 
health illness or substance abuse concerns are more likely to 
undergo liver biopsy. We suspect that this reflects a bias by 
clinicians to favor pursuit of therapy only in those with advanced 
stages of liver fibrosis, given the negative effect of interferon on 
these conditions. Our analysis of treatment initiation importantly 
suggests that mental health illness does not negatively influence 
starting therapy. Furthermore, we demonstrated that despite 
concurrent HIV infection and other barriers to care, liver 
fibrosis stage was the single most important variable influencing 
whether a patient initiates therapy.
Immigration status, race, language barriers and 
socioeconomic factors impede access to HCV-related health 
care in developed regions of the world.6,7,21–24 Our analyses Therapeutics and Clinical Risk Management 2010:6 211
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suggest that these issues do not inevitably lead to substandard 
HCV care, irrespective of HIV status. Several factors may 
have facilitated the equity of care achieved in our setting. 
The Canadian health care system is publicly funded and 
universal in access. The likelihood of visiting a physician is 
primarily related to health care needs and chronic conditions 
but less influenced by socioeconomic status and education 
level.25,26 Although access to care disparities should not exist 
within this system, lower socioeconomic and educational 
levels have nonetheless been associated with a reduced 
likelihood of referral to specialist care.25,27,28 There is a long 
history of managing diverse populations within our urban, 
hospital-based clinics. Our staff is aware of these obstacles 
and as a consequence makes a concerted effort to provide 
equal care to all patients. As well, the institutional emphasis 
on equal access to health care services in both French and 
English likely increases health care provider awareness of 
language barriers, thereby reducing the potential negative 
impact of this obstacle to care.
Consistent with our previous findings and other reports, 
HIV co-infection is a key predictor of reduced SVR with 
HCV treatment.1,4,29 Our analysis suggests that concomitant 
barriers to successful treatment outcome, which include 
poverty, language barriers and mental health disease, did not 
further diminish overall SVR and specifically in HIV–HCV 
co-infection. In other words, the reduced SVR in those with 
HIV–HCV co-infection appears to be entirely biological in 
nature and not due to concurrent barriers to therapeutic success. 
Although limited by sample size, our findings suggest that the 
concurrent use of cART or specific antiretrovirals does not 
influence the likelihood of achieving a SVR.
There are strengths and limitations to consider when 
interpreting our analysis. Strengths include dataset integrity. 
The dataset used for this retrospective database evaluation 
had minimal missing data and was carefully assessed for 
inaccuracies prior to conducting the statistical analysis. 
Limitations of our study include its retrospective design, 
single site evaluation, and a lack of generalizability to 
nonpublicly-funded sites. However, our clinic population of 
HIV–HCV co-infected and HCV mono-infected patients are 
similar in characteristics to other North American, European, 
and Australian populations.30 Therefore, we believe that 
these results are broadly applicable. A high proportion of our 
patients were White which also influences generalizability.
Our study found that equitable access to HCV care in 
  HIV–HCV co-infection can be achieved in spite of the 
presence of well-established barriers to health care provision 
and outcomes. The influence of these obstacles may be elimi-
nated by recognizing their potential to diminish the quality of 
and access to care and establishing a health care infrastructure 
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Figure 1 Sustained virological response by HIV status and genotype.
Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus.Therapeutics and Clinical Risk Management 2010:6
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that can provide the complex care required by this population. 
Health care provision by a publicly funded, multidisciplinary 
team appears to facilitate the delivery of equitable care to those 
living with HCV , irrespective of HIV co-infection.
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